BioSpace News Archive

Helius Medical Technologies, a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, announced that it will be showcasing its breakthrough Portable Neuromodulation Stimulator technology at the American Physical Therapy Association Combined Sections Meeting.

Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain (CLBP), announced today their presence at the 2nd Annual Sonntag Spine Symposium on Friday, February 17, hosted by Barrow Neurological Institute.

EuMentis Therapeutics Inc., a privately held biopharmaceutical company developing novel therapeutics for the treatment of neuropsychiatric and neurodevelopmental disorders, including its lead clinical-stage programs for ASD and TS, announced the closing of $20 million of a targeted $40 million Series B financing from a private family office.

Shanghai Henlius Biotech, Inc. (2696.HK) announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for Henlius’ HLX02 (trastuzumab for injection, trade name in Europe: Zercepac®, trade name in China: HANQUYOU; trade names in Australia: Tuzucip® and Trastucip®) submitted by the company’s business partner Accord BioPharma Inc. (Accord US).

Glaukos Corporation announced that its management is scheduled to participate in the Citi Healthcare Conference on Wednesday, March 1, 2023, at 1:15 p.m. ET in New York City.

Waters Corporation announced its financial results for the fourth quarter and full-year 2022.

Unravel Biosciences, Inc., (“Unravel”), a therapeutics company that leverages a machine-learned model of human health to advance drugs for complex diseases, today announced the successful completion of its Type B pre-IND meeting with the U.S. Food and Drug Administration (FDA) for its RVL001 program in Rett Syndrome.

Harrow announced the launch of its patent-pending, next-generation compounded Atropine formulations, which are now available through Harrow’s wholly owned compounding and mail order pharmacy subsidiary, ImprimisRx.

AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today announced positive final results from a Phase 2 study of posoleucel, an investigational, allogeneic, off-the-shelf, multi-virus-specific T cell (VST) therapy, being studied for the treatment of BK viremia (BKV) in adult kidney transplant recipients.

Novocure (NASDAQ: NVCR) today announced that the final patient has been enrolled in the pivotal PANOVA-3 study evaluating the efficacy of Tumor Treating Fields (TTFields) together with nab-paclitaxel and gemcitabine for treatment of patients with locally advanced pancreatic cancer.